Pharsight — Q4 2007 Earnings Presentation
45 slides from Pharsight's earnings presentation, May 14, 2007

Slide 1: Pharsight Corporation Investor Presentation
Exhibit 99.1 Pharsight Corporation Investor Presentation 4th Quarter Fiscal 2007 Update March 31, 2007 Shawn O’Connor President, Chairman and CEO Will Frederick CFO Confidential © Pharsight Corporation

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements, including statements regarding our financial model, growth opportunities and strategic investments, our market position, the demand and market opportunity for our products and services, financial and product performanc

Slide 3: Overview
Overview • Profile – Founded in 1995 with IPO in August 2000 – Offices in Mountain View, CA (HQ) and Cary, NC (R&D) – Global headcount approximately 90 – Stock traded OTCBB: PHST • Key Industry Considerations – Large Pharmaceutical and biotech marketplace – Outsourcing of development activities esca

Slide 4: Pharsight Capabilities Supporting Efficient Drug Development
Pharsight Capabilities Supporting Efficient Drug Development Strategic Consulting Reporting and Software Products Services Analysis Services Improve productivity and Quantify your decision- Outsource reporting and compliance making analysis Enterprise and desktop products Consulting expertise in mod

Slide 5: FDA Influence Driving Market Adoption
FDA Influence Driving Market Adoption FDA and Pharsight sign CRADA - June 2006 • Pharsight will make available a comprehensive suite of software tools, including: Pharsight ® Knowledgebase Server™ (PKS™), PKS Validation Suite™, WinNonlin ® Validation Suite™, Trial Simulator™-and Drug Model Explorer™

Slide 6: Market Opportunity: Drug Development Cost and Timeline
Market Opportunity Drug Development Cost and Timeline Research Clinical Development $25 Billion 1 $48 Billion 1 • High throughput screening • Long, risky and complex process • Combinatorial chemistry • Of 5,000 screened • Genomics compounds: 250 enter preclinical testing, 5 • Rational drug design en

Slide 7: Market Opportunity: Software Product Diversification
Market Opportunity Software Product Diversification • Customers expanding their use of the Pharsight family of products can create $100K to $500K+ in initial revenue and increases of 15x in ongoing maintenance revenue $90K+ maint. $90K After Diversification Before WNL Enterprise Diversification WNL

Slide 8: Current Customers Includes All Top 50 Pharma Companies
Current Customers Includes All Top 50 Pharma Companies Copyright © 2007 Pharsight Corporation. All rights reserved. 8

Slide 9: Software Products
Software Products Confidential © Pharsight Corporation

Slide 10: Software Products Overview
Software Products Overview • Analytics – WinNonlin ® – WinNonMix ® – Trial Simulator™ – IVIVC Toolkit™ for WinNonlin • Data Management & Compliance – Pharsight ® Knowledgebase Server™ – PKS Reporter – WinNonlin AutoPilot™ • Validation – WinNonlin Validation Suite™ – PKS Validation Suite™ • Model Vis

Slide 11: Software Products Market Acceptance
Software Products 1 Market Acceptance • Over 1,250 active software customers 2 • All Top 50 Pharma license at least one of our software products • Our software applications are licensed for use on more than 6,700 desktops in industry and academia 2 TM • 13 of the Top 50 Pharma are PKS customers – 19

Slide 12: Software Products Return on Investment Example: Pfizer
Software Products Return on Investment Example Pfizer “Within 2 years of (implementing Pharsight’s WinNonlin automation and other measures) the two people conducting the routine pharmacokinetic studies had completed 45 studies in 1 year.” (previous staff of 19 for the same work) “The cycle time to i

Slide 13: WinNonlin (WNL)
Software Products WinNonlin ® (“WNL™”) Industry Gold-Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD”) Modeling, and Non Compartmental Analysis • Key Benefits – Used to simulate effects of different dosing regimens and changes in pharmacokinetic parameters required in regulatory submission

Slide 14: WinNonMix (WNM)
Software Products WinNonMix ® (“WNM™”) Nonlinear Mixed Effects (Population) Analysis Software Application • Key Benefits – Extensive built-in library of PK, PD and PK-PD models – NONMEM data import wizard – Built-in report-ready graphics capability – Estimation algorithms for sparse and for rich dat

Slide 15: Trial Simulator
Software Products Trial Simulator™ State-of-the-Art Clinical Trial Design and Simulation Software • Key Benefits – Minimize risk of trial design – Formalize assumptions – Quantify uncertainty – Reduce cost of clinical trials and drug development time-to-market • Potential Growth Drivers – Increase p

Slide 16: IVIVC Toolkit for WinNonlin
Software Products IVIVC Toolkit™ for WinNonlin In vivo-in vitro correlations (IVIVC) • Key Benefits – Speed formulation development – Improve success of bioequivalence studies – Reduce expense and time needed for in vivo studies • Potential Growth Drivers – Increase interoperability with other Phars

Slide 17: Pharsight Knowledgebase Server (PKS)
Software Products Pharsight ® Knowledgebase Server™ (“PKS™”) Enterprise Data Management Systems for Secure Storage and Management of PK/PD Data • Key Benefits – Dramatically improves data management and data access – Increases productivity in analysis and reporting tasks – Supports compliance with F

Slide 18: WinNonlin AutoPilot
Software Products WinNonlin AutoPilot™ Streamlining Routine Clinical PK Analyses and Reporting • Key Benefits – Capture and implement best practices and business rules within a department and across sites. – Standardize content and formatting of analyses and reports to reduce authoring/review effort

Slide 19: Drug Model Explorer (DMX)
Software Products Drug Model Explorer™ (“DMX ® ”) Software-Based Communication Technology, Designed to Facilitate Quantitative Decision-Making in Drug Development • Key Benefits – Facilitates more efficient collaboration within project teams to explore key drug attributes, and their respective uncer

Slide 20: Strategic Consulting Services
Strategic Consulting Services Confidential © Pharsight Corporation

Slide 21: Strategic Consulting Services Overview
Strategic Consulting Services Overview • World-class experts in clinical pharmacology, PK/PD, decision analysis, and statistics • Rich mix of drug development experience from industry, academic and consulting backgrounds • Consulting engagements completed in all major therapeutic areas and indicatio

Slide 22: Strategic Consulting Services Market Acceptance
Strategic Consulting Services Market Acceptance 1 • Over 40 active consulting clients in Fiscal 2007 2 – 19 of the Top 50 Pharma were active consulting clients – 24 new consulting clients • Over 140 projects engaged during Fiscal 2007 • Diverse Customer Workplans – Hourly engagements to annual engag

Slide 23: Broad Modeling Capabilities
Strategic Consulting Services Broad Modeling Capabilities Quantitative decision support provided on multiple projects in all phases of drug development across most major therapeutic areas and for a variety of indications Pre- Phase Phase Phase Therapeutic Area Phase I Clinical II III IV Anti-infecti

Slide 24: Strategic Consulting Services Customer Value
Strategic Consulting Services Customer Value • A complete analysis of your next decision and a recommendation • Quantification of the size of the risk you take in your next decision • Information on your project of the type increasingly requested by the FDA • Access to some of the world’s leading ex

Slide 25: Strategic Consulting Services Growth Drivers
Strategic Consulting Services Growth Drivers • Industry Factors – Increased acceptance of modeling and simulation to achieve efficient drug development decision making – FDA Critical Path Initiative advocates increased use of modeling and simulation to overcome poor development productivity – Increa

Slide 26: Strategic Consulting Services Revenue Diversification
Strategic Consulting Services 1 Revenue Diversification Successful Diversification Efforts with Reduced Revenue Dependency on “Top 2 Clients” FY07 FY06 38% 48% Top 2 clients Top 2 clients 52% Others Others 62% $9.3M Revenue $10.9M Revenue 1 As of March 31, 2007 Copyright © 2007 Pharsight Corporation

Slide 27: Return on Investment Example: sanofi-aventis
Strategic Consulting Services Return on Investment Example sanofi-aventis Aventis turned to a computer model from … Pharsight. Using its own animal and human test data, Aventis was able to simulate later-stage clinical trials. Based on that simulation, “we stopped funding development of the compound

Slide 28: Reporting and Analysis Services
Reporting and Analysis Services Confidential © Pharsight Corporation

Slide 29: Reporting and Analysis Services Overview
Reporting and Analysis Services Overview • Reporting and analysis of early- phase, regulatory- required studies • Complements software and Strategic Consulting Services • New services create deeper relationships with our clients • Leverages value of Pharsight brand in PK/PD • Provides a new source o

Slide 30: Reporting and Analysis Services Growth Drivers
Reporting and Analysis Services Growth Drivers • Industry Factors – Large, established market – Increased usage of outsourced capabilities – New requirements for analysis-intensive studies – Growing diversification to new delivery platforms • Internal Factors – Existing relationships with software a

Slide 31: Financial Overview
Financial Overview Confidential © Pharsight Corporation

Slide 32: Accomplishments and Guidance
Accomplishments and Guidance FY07 Accomplishments FY08 Guidance • Revenue growth • Continued revenue growth – Y/Y revenue growth of 10% – Y/Y revenue growth of approx. 10% to th 15%, or approx. $27.5M - $29M – 4 consecutive year of revenue growth • Gross Margin • Gross Margin – 69% of revenue – Appr

Slide 33: Summary Income Statements
Summary Income Statements (in thousands) FY07 FY06 Consol. SPBU SCS Consol. SPBU SCS Revenue 25,092 14,238 10,854 22,742 13,449 9,293 Y/Y growth 10% 6% 17% 1% 11% -12% Cost of revenue 7,731 1,383 6,348 7,699 1,789 5,910 Gross profit 17,361 12,855 4,506 15,043 11,660 3,383 Gross margin 69% 90% 42% 66

Slide 34: Summary Balance Sheets
Summary Balance Sheets (in thousands) March 31, March 31, 2007 2006 ASSETS Cash & short term investments $ 14,665 $ 10,832 Accounts receivable, net 3,087 4,585 Total current assets 18,275 15,715 Total assets $ 19,995 $ 17,786 LIABILITIES & STOCKHOLDERS' DEFICIT A/P & accrued expenses $ 4,389 $ 3,981

Slide 35: Annual Revenue by Business Unit
Annual Revenue by Business Unit (in thousands) $30,000 $25,000 $20,000 $15,000 $10,000 $5,000 $0 FY04 FY05 FY06 FY07 FY08 Guidance Software Products Strategic Consulting Guidance ($27.5M - $29M) Copyright © 2007 Pharsight Corporation. All rights reserved. 35

Slide 36: Quarterly Revenue by Business Unit
Quarterly Revenue by Business Unit (in thousands) $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 $0 Q4 FY06 Q1 FY07 Q2 FY07 Q3 FY07 Q4 FY07 Software Products Strategic Consulting Copyright © 2007 Pharsight Corporation. All rights reserved. 36

Slide 37: Annual Gross Profit
Annual Gross Profit (in thousands) $17,500 $15,000 $12,500 $10,000 $7,500 $5,000 $2,500 $0 FY03 FY04 FY05 FY06 FY07 Copyright © 2007 Pharsight Corporation. All rights reserved. 37

Slide 38: Annual Operating Income
Annual Operating Income (in thousands) $5,000 $2,500 $0 -$2,500 -$5,000 -$7,500 -$10,000 -$12,500 FY03 FY04 FY05 FY06 FY07 Note: FY07 Operating Income reflects $831 for stock-based compensation expense Copyright © 2007 Pharsight Corporation. All rights reserved. 38

Slide 39: Annual Operating Cash Flow
Annual Operating Cash Flow (in thousands) $6,000 $4,000 $2,000 $0 -$2,000 -$4,000 -$6,000 -$8,000 FY03 FY04 FY05 FY06 FY07 Copyright © 2007 Pharsight Corporation. All rights reserved. 39

Slide 40: Equity Overview
Equity Overview 1 • Common Shares Outstanding 20 million 1 • Preferred Shares Outstanding 8 million – 1.8 million Series A and 0.2 million Series B – Conversion ratio to Common at 4:1 1 • Common Equivalent Shares (as converted) 28 million • PIPE Financing 6/02 and 9/02 = $7.5 million – 1.8 million U

Slide 41: Significant Shareholders
1 Significant Shareholders Alloy Entities 16% ownership McKesson Corp. 14% ownership Sprout Entities 9% ownership Weiss Peck & Greer 6% ownership Wellington Management Co. 4% ownership Perritt Capital Management 1% ownership Lewis Asset Management Corp. 1% ownership 1 Excludes Preferred Shares outst

Slide 42: Executive Team
Executive Team Shawn M. O’Connor President, Chairman and Chief Executive Officer QRS, Diasonics Ultrasound, Peat Marwick Will Frederick Chief Financial Officer Versata, Clarent, ACT Networks, Disney Daniel Weiner, PhD Chief Technology Officer IVAX, Merrell Dow, Syntex, Quintiles James Hayden SVP Glo

Slide 43: Summary
Summary • Current pharmaceutical market trends look favorable… • Increasing mindshare for quantitative-based modeling and simulation… • FDA's call for more modeling and simulation in the Critical Path Initiative… • Financially stable and leveragable business model… All support our drive towards expa

Slide 44: Proprietary Notice
Proprietary Notice All contents Copyright ©2007 Pharsight Corporation. All rights reserved. The copyright for this document is owned by Pharsight Corporation. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, for

Slide 45: Pharsight
Pharsight Pharsight
Source: SEC EDGAR · 8-K filed May 14, 2007
More decks from Pharsight Corp
Investor Presentation (January 2007)41 slides · Jan 26, 2007
Q2 2007 Earnings Presentation33 slides · Nov 30, 2006
Q1 FY2007 Earnings Presentation37 slides · Aug 3, 2006
Investor Presentation (June 2006)36 slides · Jun 6, 2006
Investor Presentation (February 2006)31 slides · Feb 2, 2006
Investor Presentation (August 2005)39 slides · Aug 2, 2005